NCT01317186

Brief Summary

In chronic kidney disease calcium (Ca) and phosphate (P) metabolism disorders are very common and also they are one of the leading causes of morbidity in these population. FGF23 is a novel factor that contributes Ca-P disorders. It has been hypothesized that FGF 23 increase is mediated by asymmetric dimethylarginine (ADMA). The aim of the study is to evaluate this hypothesis.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2011

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

March 16, 2011

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 17, 2011

Completed
Last Updated

March 17, 2011

Status Verified

March 1, 2011

First QC Date

March 16, 2011

Last Update Submit

March 16, 2011

Conditions

Metabolic DiseasesChronic Kidney Disease

Keywords

FGF 23ADMAchronic kidney diseaseCa-P metabolism disorder

Study Arms (3)

Group I

Stage 2 Non-diabetic Chronic Kidney Disease

Group II

Stage 3 Non-diabetic Chronic Kidney Disease

Group III

Stage 4 Non-diabetic Chronic Kidney Disease

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Stage 2-4 Non-diabetic Chronic Kidney Disease patients

You may qualify if:

  • between ages of 18 - 65 years old
  • chronic kidney disease of stage 2-4

You may not qualify if:

  • presence of diabetes mellitus or ischemic hearth disease
  • taking vitamin d therapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ankara Education and Research Hospital

Ankara, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Metabolic DiseasesRenal Insufficiency, Chronic

Condition Hierarchy (Ancestors)

Nutritional and Metabolic DiseasesRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Sponsor Type
OTHER GOV

Study Record Dates

First Submitted

March 16, 2011

First Posted

March 17, 2011

Study Start

March 1, 2011

Last Updated

March 17, 2011

Record last verified: 2011-03

Locations

TU(1)